IMDX Stock Insight Molecular Diagnostics (IMDX, $4.13) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 4, 2026
at Tickeron.com
This is a Bullish indicator signaling IMDX's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 47 similar cases where IMDX's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:
IMDX sees its Stochastic Oscillator recovers from oversold territory
On September 03, 2026, the Stochastic Oscillator for IMDX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 74 instances where the indicator left the oversold zone. In 65 of the 74 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMDX's RSI Oscillator exited the oversold zone, 21 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for IMDX just turned positive on September 04, 2026. Looking at past instances where IMDX's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
Following a +3.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMDX as a result. In 83 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (196.078) is normal, around the industry mean (60.137). P/E Ratio (0.000) is within average values for comparable stocks, (156.768). IMDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.504). IMDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). IMDX's P/S Ratio (85.470) is very high in comparison to the industry average of (9.865).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.